CenTrial Logo

Is Mepolizumab Effective In Reducing Need for Sinus Surgery?


Clinical trial finds that mepolizumab reduces the need for sinus surgery in patients with chronic rhinosinusitis and nasal polyps

Nasal polyps are small, non-cancerous growths that develop in the lining of the nose and sinuses. Chronic rhinosinusitis (CRS) is a condition characterized by inflammation of the nasal and sinus passages that persists for more than 12 weeks. Nasal polyps can develop as a complication of CRS, particularly in patients with severe disease. CRS with nasal polyps (CRSwNP) can cause various symptoms, including nasal congestion, runny nose, reduced sense of smell, facial pressure or pain, and postnasal drip. These symptoms can significantly impact a patient's quality of life and ability to function normally.

The exact cause of nasal polyps in CRS is not fully understood, but it is thought to be related to an abnormal immune response in the nasal and sinus tissues. This response can lead to chronic inflammation, which can trigger the growth of polyps. Treatment for CRSwNP typically involves a combination of medications, such as corticosteroids and nasal sprays, and surgery. Surgery is generally reserved for patients who do not respond to drugs or have recurrent polyps. However, even after surgery, nasal polyps can recur in up to 75% of patients with CRSwNP.

Mepolizumab, a drug that targets a specific type of white blood cell called eosinophils, has been shown to reduce the need for sinus surgery in a clinical trial called SYNAPSE. A follow-up study aimed to provide more detailed information about the effect of mepolizumab on surgery endpoints in the SYNAPSE trial. The trial included adults with recurrent, refractory, severe CRSwNP eligible for repeat sinus surgery. Patients were randomized to receive mepolizumab or a placebo and standard care every four weeks for 52 weeks.

Are you interested in clinical trials near you?

You can receive free notification of a trial for this, or any other condition, by completing a short confidential health profile.
Find a clinical trial near me
The study found that mepolizumab reduced the risk of patients being included on a waiting list for sinus surgery at week 52 compared to the placebo. Additionally, mepolizumab reduced the risk of sinus surgery regardless of the time since the patient's last sinus surgery before study screening and their baseline blood eosinophil count.

These findings suggest that mepolizumab could be a beneficial treatment option for patients with severe CRSwNP who require repeat sinus surgery. By reducing the need for surgery, mepolizumab could improve the quality of life for these patients and reduce the burden on healthcare systems. However, further research is needed to confirm these findings and determine mepolizumab's long-term safety and efficacy in this patient population.
National Library of Medicine, Mar-23
ClinicalTrials.gov NCT03085797

Share this article with a friend:

Get emailed clinical trial results in the categories of your choice:
Free subscription to clinical trial results

Signup to be notified of clinical trials near you that match your condition

Signup and be matched to trials near you
This free service will notify you of current and future clinical trial matches.

This content is for informational and educational purposes only. It is not intended to provide medical advice or to take the place of such advice or treatment from a personal physician. All readers/viewers of this content are advised to consult their doctors or qualified health professionals regarding specific health questions. CenTrial Data Ltd. does not take responsibility for possible health consequences of any person or persons reading or following the information in this educational content. Treatments and clinical trials mentioned may not be appropriate or available for all trial participants. Outcomes from treatments and clinical trials may vary from person to person. Consult with your doctor as to whether a clinical trial is a suitable option for your condition. Assistance from generative AI tools may have been used in writing this article.